Social Isolation and Aging in Schizophrenia
Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical conditions that nor
| Condition(s) | Schizophrenia and Related Disorders |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical conditions that normally occur later in life, a process known as 'accelerated aging'. While unhealthy lifestyle behaviors, such as smoking and unhealthy diet, account, in part, for accelerated aging in SZ, the excess of physical comorbidities cannot be solely attributed to these factors. Remarkably, the direct adverse health effects of key clinical characteristics of SZ have rarely been considered. In the general population, the absence of social contact is known to pose enormous challenges for |
| Who can participate | Inclusion and exclusion criteria for participants with SZ: * DSM-IV or V diagnosis of a SZ related disorder (295.x, 297.1, 298.8, or 298.9; e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, but not psychotic disorder that is solely substance induced) based on clinical interview; * Between 40 and 70 years of age at time of study recruitment; * Participant was enrolled in a previous research study between the ages of 20-55, and this study took place at least 5 years ago; * Able to understand the spoken language of the participating country sufficiently to comprehend testing procedures; * No history of serious head injury (i.e., loss of consciousness longer than 1 hour, no neuropsychological sequelae, no cognitive rehabilitation treatment post head injury); * No histor |
| Ages | 40 Years to 70 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
| Locations | Hartford, Connecticut, United States; Amsterdam, North Holland, Netherlands; Madrid, Spain; London, United Kingdom |
| Start date | 2024-01-09 |
| NCT ID | NCT07419321 |
| Official listing | https://clinicaltrials.gov/study/NCT07419321 |